Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Xenon Pharmaceuticals (XENE). Shares have added about 8.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Xenon Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, fresh estimates flatlined during the past month.VGM ScoresCurrently, Xenon Pharmaceuticals has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookXenon Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerXenon Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Celldex Therapeutics (CLDX), has gained 6.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.Celldex reported revenues of $0.69 million in the last reported quarter, representing a year-over-year change of +331.3%. EPS of -$0.81 for the same period compares with -$0.56 a year ago.For the current quarter, Celldex is expected to post a loss of $0.86 per share, indicating a change of -59.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.2% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Celldex. Also, the stock has a VGM Score of F.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Xenon Pharmaceuticals Inc. (XENE): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks